Heterologous prime-boost immunization with live SPY1 and DnaJ protein of Streptococcus pneumoniae induces strong Th1 and Th17 cellular immune responses in mice.

Publisher: Microbiological Society Of Korea Country of Publication: Korea (South) NLM ID: 9703165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1976-3794 (Electronic) Linking ISSN: 12258873 NLM ISO Abbreviation: J Microbiol Subsets: MEDLINE

Original Publication: Seoul : Microbiological Society Of Korea

Immunization*; HSP40 Heat-Shock Proteins/*immunology ; Immunity, Cellular/*immunology ; Pneumococcal Infections/*prevention & control ; Streptococcus pneumoniae/*metabolism ; Th1 Cells/*immunology ; Th17 Cells/*immunology ; Vaccines, Attenuated/*immunology; Administration, Intranasal ; Animals ; Antibodies, Bacterial/blood ; Antigens, Bacterial/genetics ; Antigens, Bacterial/immunology ; Cloning, Molecular ; Colony Count, Microbial ; Cytokines/metabolism ; Escherichia coli/genetics ; Female ; Gene Expression Regulation, Bacterial ; HSP40 Heat-Shock Proteins/administration & dosage ; HSP40 Heat-Shock Proteins/genetics ; Immunoglobulin G/blood ; Lung/microbiology ; Lung/pathology ; Mice ; Mice, Inbred BALB C ; Pneumococcal Infections/immunology ; Recombinant Proteins/genetics ; Recombinant Proteins/immunology ; Respiratory System/microbiology ; Streptococcus pneumoniae/drug effects ; Streptococcus pneumoniae/genetics ; Streptococcus pneumoniae/pathogenicity ; Vaccination

Streptococcus pneumoniae is a leading cause of infectious diseases in children under 5-year-old. Vaccine has been used as an indispensable strategy to prevent S. pneumoniae infection for more than 30 years. Our previous studies confirmed that mucosal immunization with live attenuated strain SPY1 can protect mice against nasopharyngeal colonization of S. pneumoniae and lethal pneumococcal infection, and the protective effects are comparable with those induced by commercially available 23-valent polysaccharide vaccine. However, live attenuated vaccine SPY1 needs four inoculations to get satisfactory protective effect, which may increase the risk of virulence recovery. It is reported that heterologous primeboost approach is more effective than homologous primeboost approach. In the present study, to decrease the doses of live SPY1 and improve the safety of SPY1 vaccine, we immunized mice with SPY1 and DnaJ protein alternately. Our results showed that heterologous prime-boost immunization with SPY1 and DnaJ protein could significantly reduce the colonization of S. pneumoniae in the respiratory tract of mice, and induce stronger Th1 and Th17 cellular immune responses than SPY1 alone. These results indicate heterologous prime-boost immunization method not only elicits better protective effect than SPY1 alone, but also reduces the doses of live SPY1 and decreases the risk of SPY1 vaccine. This work is the first time to study the protective efficiency with two different forms of S. pneumoniae candidate vaccine, and provides a new strategy for the development of S. pneumoniae vaccine.

Am J Reprod Immunol. 2015 Oct;74(4):302-8. (PMID: 25917014)
J Biomed Biotechnol. 2010;2010:174378. (PMID: 20368780)
Clin Microbiol Rev. 2011 Jul;24(3):557-91. (PMID: 21734248)
Mol Immunol. 2015 Aug;66(2):384-91. (PMID: 25968974)
Vet J. 2010 Feb;183(2):210-6. (PMID: 19008134)
PLoS Pathog. 2008 Sep 19;4(9):e1000159. (PMID: 18802458)
Lancet. 2011 Dec 3;378(9807):1962-73. (PMID: 21492929)
Vaccine. 2011 Feb 17;29(9):1736-44. (PMID: 21238570)
PLoS One. 2015 Apr 09;10(4):e0122835. (PMID: 25856308)
Clin Sci (Lond). 2016 May;130(9):697-710. (PMID: 26831937)
Lancet Infect Dis. 2004 Mar;4(3):144-54. (PMID: 14998500)
Infect Immun. 2007 May;75(5):2469-75. (PMID: 17339359)
Lancet Infect Dis. 2011 Dec;11(12):889-91. (PMID: 21975267)
Curr Opin Immunol. 2009 Jun;21(3):346-51. (PMID: 19500964)
Sci Rep. 2015 Jan 14;5:7771. (PMID: 25586780)
Vaccine. 2014 Jul 16;32(33):4179-88. (PMID: 24945468)
Infect Immun. 2010 Mar;78(3):1276-83. (PMID: 20038538)
J Infect Dis. 2005 Oct 1;192(7):1237-44. (PMID: 16136467)
J Infect Dis. 2010 Jan 1;201(1):32-41. (PMID: 19947881)
Mucosal Immunol. 2015 May;8(3):627-39. (PMID: 25354319)
Wkly Epidemiol Rec. 2012 Apr 6;87(14):129-44. (PMID: 24340399)
PLoS One. 2008;3(11):e3790. (PMID: 19023426)
J Biotechnol. 1996 Jan 26;44(1-3):225-31. (PMID: 8717408)
J Microbiol. 2012 Jun;50(3):511-7. (PMID: 22752916)
Infect Immun. 2015 Jan;83(1):90-100. (PMID: 25312946)
Wkly Epidemiol Rec. 2013 Apr 26;88(17):173-80. (PMID: 23696979)
J Microbiol. 2014 Apr;52(4):315-23. (PMID: 24682994)
Vaccine. 2011 Aug 5;29(34):5731-9. (PMID: 21696869)
Mucosal Immunol. 2017 Jan;10 (1):250-259. (PMID: 27118490)
Infect Immun. 2014 Apr;82(4):1666-75. (PMID: 24491576)
Vaccines (Basel). 2013 Dec 27;2(1):36-48. (PMID: 26344467)
Lancet. 2009 Sep 12;374(9693):893-902. (PMID: 19748398)
Curr Opin Immunol. 2011 Jun;23(3):407-13. (PMID: 21514128)
Curr Infect Dis Rep. 2014 Apr;16(4):403. (PMID: 24659399)

Keywords: Streptococcus pneumonia; heterologous prime-boost; vaccine

0 (Antibodies, Bacterial)
0 (Antigens, Bacterial)
0 (Cytokines)
0 (HSP40 Heat-Shock Proteins)
0 (Immunoglobulin G)
0 (Recombinant Proteins)
0 (Vaccines, Attenuated)

Date Created: 20170929 Date Completed: 20180420 Latest Revision: 20181113

20250114

10.1007/s12275-017-7262-1

28956354